Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid for 4 Weeks in Prosthetic Joint Infections After Implant Removal
2018-002465-18Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tedizolid in periprosthetic joint infection (PJI), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Investigator-assessed clinical outcome at 6 months after tedizolid. Started Aug 2019; status: completed.
02
Drugs
tedizolid
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2018-002465-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002465-18.